ASX Share rice
Sun 01 Aug 2021 - 06:42:pm (Sydney)

ZLD Share Price

ZELIRA THERAPEUTICS LIMITEDZLDPharmaceuticals, Biotechnology & Life Sciences

ZLD Company Information


Zelira Therapeutics Limited





GIC Industry:


GIC Sub Industry:



101 St Georges Terrace Perth WA Australia 6000


61 8 6558 0886

Founder & Chairman:

Mr. Osagie O. Imasogie

Co-Founder & Non-Exec. Deputy Chairman:

Mr. Harry Karelis B.Sc (Hons), MBA, CFA, F.Fin, FAICD

Co-Founder & Non-Exec. Director:

Mr. Jason William Peterson

CEO of USA, MD of USA & Director:

Dr. Oludare Odumosu

Company Sec.:

Mr. Timothy Ryan Slate

Clinical Trial Consultant:

Dr. Patty Washer

Company Overview:

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based formulations for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and licenses in Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company is also involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It has a strategic partnership with CannPal Pty Ltd; and St Vincent's Hospital on opioid reduction study. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited is based in Perth, Australia.

ZLD Share Price Information

Shares Issued:


Market Capitalisation:


Revenue (TTM):


Revenue Per Share (TTM):


Earnings per Share:


Operating Margin (TTM):


Return On Assets (TTM):


Return On Equity (TTM):


Quarterly Revenue Growth (YOY):


Gross Profit(TTM):


Diluted Earnings Per Share (TTM):


ZLD CashFlow Statement

CashFlow Date:




Change To Liabilities:


Total Cashflow From Investing Activities:


Net Income:


Total Cash From Operating Activities:




Other Cashflow From Investing Activities:


Change To Account Receivables:


Sale Purchase Of Stock:


Capital Expenditures:


ZLD Income Statement

Income Date:


Income Before Tax:


Net Income:


Operating Income:


Other Operating Expenses:


Interest Expense:


Total Revenue:


Total Operating Expenses:


ZLD Balance Sheet

Balance Sheet Date:


Intangible Assets:


Total Liabilities:


Total Stockholder Equity:


Other Current Liabilities:


Total Assets:


Common Stock:


Other Current Assets:


Retained Earnings:


Good Will:




Total Current Liabilities:


Property - Plant & Equipment:


Net Tangible Assets:


Long-Term Investments:


Total Current Assets:


Net Receivables:


Short-Term Investments:


Accounts Payable:


Short-Term Investments:


Non Current Liabilities Total:


ZLD Share Price History

ZLD News

29 Jun, 2021
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
31 Dec, 2020
Richard Hopkins has been the CEO of Zelira Therapeutics Limited ( ASX:ZLD ) since 2018, and this article will examine...
15 Dec, 2020
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the development of clinically validated cannabis medicines, is pleased to announce it has entered into a binding licensing agreement with Alternative Solutions, a licensed grower, manufacturer and distributor of medical cannabis products in the District of Columbia (Washington DC). Under the agreement, Alternative Solutions will produce and distribute the HOPE™ line of products, Zelira's top-selling treatment developed for autism patients, throughout the legal DC medical cannabis market beginning in Q2 2021.